Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 262-273 , October 2004

The reproductive tract

  • Hossein Jadvar, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
    • Corresponding Author InformationAddress reprint requests to H. Jadvar, MD, PhD, Assistant Professor of Radiology and Biomedical Engineering, Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, 1200 N. State Street, GNH 5250, Los Angeles, CA 90033.
    • ,
  • Peter S. Conti, MD, PhD

      Affiliations

    • Division of Nuclear Medicine, Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

References 

  1. National Cancer Institute Surveillance, Epidemiology, and End Results (NCI-SEER) Program . Available at http://seer.cancer.gov 2003; accessed July 8, 2004
  2. Gusberg SB , Runowicz CD . Gynecologic Cancers . In:  Holleb AI ,  Fink DJ ,  Murphy GP editor. Clinical Oncology . Atlanta, GA: American Cancer Society; 1991;p. 481–497
  3. Follen M , Levenback CF , Iyer RB , et al.   Imaging in cervical cancer . Cancer . 2003;98:2028–2038
  4. Kerr IG , Manji MF , Powe J , et al.   Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix (A retrospective review) . Gynecol Oncol . 2001;81:477–480
  5. Kuhnel G , Horn LC , Fischer U , et al.   18F-FDG positron emission tomography in cervical carcinoma (preliminary findings) . Zentralbl Gynakol . 2001;123:229–235
  6. Rose PG , Adler LP , Rodriguez M , et al.   Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging (A surgicopathologic study) . J Clin Oncol . 1999;17:41–45
  7. Sugawara Y , Eisbruch A , Kosuda S , et al.   Evaluation of FDG PET in patients with cervical cancer . J Nucl Med . 1999;40:1125–1131
  8. Shimotsu Y , Ishida Y , Fukuchi K , et al.   Fluorine-18-fluorodeoxyglucose PET identification of cardiac metastasis arising from uterine cervical carcinoma . J Nucl Med . 1998;39:2084–2087
  9. Aizer-Dannon A , Bar-Am A , Ron IG , et al.   Fused functional-anatomic images of metastatic cancer of cervix obtained by a combined gamma camera and X-ray tube hybrid system with an illustrative case and review of the (18)F-fluorodeoxyglucose literature . Gynecol Oncol . 2003;90:453–457
  10. Yen TC , See LC , Lai CH , et al.   18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression . J Nucl Med . 2004;45:22–29
  11. Lin WC , Hung YC , Yeh LS , et al.   Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings . Gynecol Oncol . 2003;89:73–76
  12. Yeh LS , Hung YC , Shen YY , et al.   Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings . Oncol Rep . 2002;9:1289–1292
  13. Narayan K , Hicks RJ , Jobling T , et al.   A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer (potential impact on treatment) . Int J Gynecol cancer . 2001;11:263–271
  14. Reinhardt MJ , Ehritt-Braun C , Vogelgesang D , et al.   Metastatic lymph nodes in patients with cervical cancer (detection with MR imaging and FDG PET) . Radiology . 2001;218:776–782
  15. Grigsby PW , Siegel BA , Dehdashti F . Lymph node staging by positron emission tomography in patients with carcinoma of the cervix . J Clin Oncol . 2001;19:3745–3749
  16. Tran BN , Grigsby PW , Dehdashti F , et al.   Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix . Gynecol Oncol . 2003;90:572–576
  17. Umesaki N , Tanaka T , Miyama M , et al.   early and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography . Oncol Rep . 2000;7:53–56
  18. Umesaki N , Tanaka T , Miyama M , et al.   The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer . Oncol Rep . 2000;7:1261–1264
  19. Havrilesky LJ , Wong TZ , Secord AA , et al.   The role of PET scanning in the detection of recurrent cervical cancer . Gynecol Oncol . 2003;90:186–190
  20. Park DH , Kim KH , Park SY , et al.   Diagnosis of recurrent uterine cervical cancer (computed tomography versus positron emission tomography) . Korean J Radiol . 2000;1:51–55
  21. Sun SS , Chen TC , Yen RF , et al.   Value of whole body 18F-fluoro-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer . Anticancer Res . 2001;21:2957–2961
  22. Jadvar H , Conti PS . FDG PET in the evaluation of women with cervical carcinoma . Radiology . 2001;221:386
  23. Ryu SY , Kim MH , Choi SC , et al.   Detection of early recurrence with 18F-FDG PET in patients with cervical cancer . J Nucl Med . 2003;44:347–352
  24. Yen TC , Ng KK , Ma SY , et al.   Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer . J Clin Oncol . 2003;21:3651–3658
  25. Ma SY , See LC , Lai CH , et al.   Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients . J Nucl Med . 2003;44:1775–1783
  26. Townsend DW , Beyer T . A combined PET/CT scanner (The path to true image fusion) . Br J Radiol . 2002;75:S24–S30
  27. Tatsumi M , Cohade C , Zellars R , et al.   Initial experience in imaging uterine cervical cancer with FDG PET-CT (Direct comparison with PET) . J Nucl Med . 2003;5(suppl):394P
  28. Beyer T , Townsend DW , Blodgett TM . Dual modality PET/CT tomography for clinical oncology . Q J Nucl Med . 2002;46:24–34
  29. Belhocine T , Thille A , Fridman V , et al.   Contribution of whole-body 18FDG PET imaging in the management of cervical cancer . Gynecol Oncol . 2002;87:90–97
  30. Malyapa RS , Mutic S , Low DA , et al.   Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer . Int J Radiat Oncol Biol Phys . 2002;54:1140–1146
  31. Dose J , Hemminger GE , Bohuslavizki KH . Therapy monitoring using FDG-PET in metastatic cervical cancer . Lancet Oncol . 2000;1:106
  32. Nakamoto Y , Eisbruch A , Achtyes ED , et al.   Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy . Gynecol Oncol . 2002;84:289–295
  33. Miller TR , Grisby PW . Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy . Int J Radiat Oncol Biol Phys . 2002;53:353–359
  34. Singh AK , Grigsby PW , Dehdashti F , et al.   FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma . Int J Radiat Oncol Biol Phys . 2003;56:489–493
  35. Grigsby PW , Siegel BA , Dehdashti F , et al.   Posttherapy surveillance monitoring of cervical cancer by FDG-PET . Int J Radiat Oncol Biol Phys . 2003;55:907–913
  36. Miller TR , Pinkus E , Dehdashti F , et al.   Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer . J Nucl Med . 2003;44:192–197
  37. Dehdashti F , Grigsby PW , Mintun MA , et al.   Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM (relationship to therapeutic response-a preliminary report) . Int J Radiat Oncol Biol Phys . 2003;55:1233–1238
  38. Belhocine T . An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers (clinical evidence and a research proposal) . Int J Gynecol Cancer . 2003;13:228–233
  39. Lapela M , Leskinen-Kallio S , Varpula M , et al.   Imaging of uterine carcinoma by carbon-11-methionine and PET . J Nucl Med . 1994;35:1618–1623
  40. Nakahara T , Fujii H , Ide M , et al.   F-18 FDG uptake in endometrial cancer . Clin Nucl Med . 2001;26:82–83
  41. Lentz SS . Endometrial carcinoma diagnosed by positron emission tomography (A case report) . Gynecol Oncol . 2002;86:223–224
  42. Belhocine T , De Barsy C , Hustinx R , et al.   Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma . Eur J Nucl Med Mol Imaging . 2002;29:1132–1139
  43. Saga T , Higashi T , Ishimori T , et al.   Clinical value of FDG-PET in the follow-up of post-operative patients with endometrial cancer . J Nucl Med . 2003;5(suppl):385P
  44. Kao CH . FDG uptake in a huge uterine myoma . Clin Nucl Med . 2003;28:249
  45. Chander S , Meltzer CC , McCook BM . Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography . Clin Nucl Med . 2002;27:22–24
  46. Lerman H , Metser U , Grisaru D , et al.   Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients (assessment by PET/CT) . J Nucl Med . 2004;45:266–271
  47. Umesaki N , Tanaka T , Miyama M , et al.   Positron emission tomography using 2-[(18)F]fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma (A case report) . Clin Imaging . 2001;25:203–205
  48. Umesaki N , Tanaka T , Miyama M , et al.   Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma (a comparison with magnetic resonance imaging and power Doppler imaging) . Gynecol Oncol . 2001;80:372–377
  49. Cher S , Lay Ergun E . Positron emission tomographic-computed tomographic imaging of a uterine sarcoma . Clin Nucl Med . 2003;28:443–444
  50. Liu RS , Hsieh HJ , Chen YJ , et al.   18F-FDG and 11C-acetate PET imaging in the post-therapy surveillance of endometrial carcinoma . J Nucl Med . 2003;5(suppl):396P
  51. Markman M . The use of PET scanning in ovarian cancer . Gynecol Oncol . 2002;85:391
  52. Koyama K , Okamura T , Kawabe J , et al.   Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors . J Nucl Med . 2003;44:353–358
  53. Fenchel S , Grab D , Nuessle K , et al.   Asymptomatic adnexal masses (correlation of FDG PET and histopathologic findings) . Radiology . 2002;223:780–788
  54. Rieber A , Nussie K , Stohr I , et al.   Preoperative diagnosis of ovarian tumors with MR imaging (Comparison with transvaginal sonography, positron emission tomography, and histologic findings) . Am J Roentgenol . 2001;177:123–129
  55. Yoshida Y , Kurokawa T , Kawahara K , et al.   Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer . AmJ Roentgenol . 2004;182:227–233
  56. Schroder W , Zimmy M , Rudlowski C , et al.   The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer . Int J Gynecol Cancer . 1999;9:117–122
  57. Turlakow A , Yeung HW , Salmon AS , et al.   Peritoneal carcinomatosis (role of 18F-FDG PET) . J Nucl Med . 2003;44:1407–1412
  58. Safaei A , Meta J , Gambhir SS , et al.   Impact of whole body PET imaging with FDG on staging and managing patients with ovarian cancer (the referring physicianʼs point of view) . J Nucl Med . 2001;5(suppl):285P
  59. Picchio M , Sironi S , Messa C , et al.   Advanced ovarian carcinoma (usefulness of ([(180F]FDG-PET in combination with CT for lesion detection after primary treatment) . Q J Nucl Med . 2000;47:77–84
  60. Bristow RE , Simpkins F , Pannu HK , et al.   Positron emission tomography for detecting clinically occult surgically respectable metastatic ovarian cancer . Gynecol Oncol . 2002;85:196–200
  61. Drieskens O , Stroobants S , Gysen M , et al.   Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer . Gynecol Obstet Invest . 2003;55:130–134
  62. Ishiko O , Honda K , Hirai K , et al.   Diagnosis of metastasis of ovarian clear cell carcinoma to the peritoneum of the abdominal wall by positron emission tomography with (fluorine-18)-2-deoxyglucose . Oncol Rep . 2001;8:67–69
  63. Kubik-Huch RA , Dorffler W , von Schulthess GK , et al.   Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma . Eur Radiol . 2000;10:761–767
  64. Zimmy M , Schroder W , Wolters S , et al.   18F-fluorodeoxyglucose PET in ovarian carcinoma (methodology and preliminary results) . Nuklearmedizin . 1997;36:228–233
  65. Jadvar H , Tatlidil R , Conti PS . FDG-PET in the evaluation of recurrent ovarian cancer . J Nucl Med . 2001;42(suppl 5):286P
  66. Ryu S , Kim J , Kim Bg , et al.   FDG-PET scan cannot substitute for second look operation in patients with ovarian cancer showing clinical complete response with chemotherapy . J Nucl Med . 2001;5(suppl):286P
  67. Manuel M , Holschneider CH , Williams CM , et al.   Correlation of FDG-PET scans with surgicopathologic findings in ovarian cancers . J Nucl Med . 2002;5(suppl):29P
  68. Holschneider CH , Manuel M , Williams CM , et al.   FDG-PET in ovarian cancer (use of the standardized uptake value (SUV) to differentiate physiological bowel cavity from intraperitoneal metastatic tumor) . J Nucl Med . 2002;5(suppl):29P
  69. Cho SM , Ha HK , Byaun JY , et al.   Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer . Am J Roentgenol . 2002;179:391–395
  70. Makhija S , Howden N , Edwards R , et al.   Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma (A retrospective review) . Gynecol Oncol . 2002;85:53–58
  71. Cohade C , Mourtziks KA , Pannu HK , et al.   Direct comparison of PET and PET/CT in the detection of recurrent ovarian cancer . J Nucl Med . 2003;5(suppl):129P
  72. Blodgett TM , Meltzer CC , Townsend DW , et al.   PET/CT in re-staging patients with ovarian carcinoma . J Nucl Med . 2002;5(suppl):310P
  73. Israel O , Keidar Z , Bar-Shalom R , et al.   Hybrid PET/CT imaging with FDG in management of patients with gynecologic malignancies . J Nucl Med . 2003;5(suppl):129P
  74. Rose PG , Faulhaber P , Miraldi F , et al.   Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma (correlation with second-look laparotomy) . Gynecol Oncol . 2001;82:17–21
  75. Hubner KF , McDonald TW , Smith GT , et al.   Detection of recurrent ovarian cancer by PET using FDG . Clin Positron Imaging . 1999;2:346
  76. Hubner KF , McDonald TW , Niethammer JG , et al.   Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG) . Gynecol Oncol . 1993;51:197–204
  77. Karlan BY , Hawkins R , Hoh C , et al.   Whole-body positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma . Gynecol Oncol . 1993;51:175–181
  78. Zimmy M , Siggelkow W , Schroder W , et al.   2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer . Gynecol Oncol . 2001;83:310–315
  79. Maldonado A , Sancho F , Perez-Carrion R , et al.   Value of FDG-PET in the therapeutic management of recurrent ovarian cancer. Experience in 31 patients . Clin Positron Imaging . 1999;2:321
  80. Smith GT , Hubner KF , McDonald T , et al.   Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET . Clin Positron Imaging . 1998;1:263
  81. Smith GT , Hubner KF , McDonald T , et al.   Cost analysis of FDG PET for managing patients with ovarian cancer . Clin Positron Imaging . 1999;2:63–70
  82. Garcia Velloso MJ , Boan Garcia J F , Villar Luque LM , et al.   F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA-125 . Rev Esp Med Nucl . 2003;22:217–223
  83. Mahy N , Mathieu I , Willemart B , et al.   The place of PET-FDG in the diagnosis of recurrent ovarian cancer . J Nucl Med . 2003;5(suppl):130P
  84. Chang WC , Hung YC , Kao CH , et al.   Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based on asymptomatically elevated serum levels of tumor marker . Neoplasma . 2002;49:329–333
  85. Torizuka T , Nobezawa S , Kanno T , et al.   Ovarian cancer recurrence (role of whole-body positron emission tomography using 2-[fluoro-18]-fluoro-2-deoxy-D-glucose) . Eur J Nucl Med Mol Imaging . 2002;29:797–803
  86. Yen RF , Sun SS , Shen YY , et al.   Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection recurrent ovarian cancer . Anticancer Res . 2001;21:3691–3694
  87. Kurokawa T , Yoshida Y , Kawahara K , et al.   Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range . Ann Nucl Med . 2002;16:491–493
  88. Yuan CC , Liu RS , Wang PH , et al.   Whole-body PET with (fluorine-18)-2-deoxyglucose for detecting recurrent ovarian carcinoma. Initial Report . J Reprod Med . 1999;44:775–778
  89. Casey MJ , Gupta NC , Muths CK . Experience with positron emission tomography (PET) scans in patients with ovarian cancer . Gynecol Oncol . 1994;53:331–338
  90. Nakamoto Y , Saga T , Ishimori T , et al.   Clinical value of positron emission tomography with FDG for recurrent ovarian cancer . AJR Am J Roentgenol . 2001;176:1449–1454
  91. Dadparvar S , Chotipanich C , Guan L , et al.   18FDG-PET imaging in detection of recurrent ovarian carcinoma . J Nucl Med . 2003;5(suppl):131P
  92. Pannu HK , Bristow RE , Cohade C , et al.   PET-CT in recurrent ovarian cancer (Initial observations) . Radiographics . 2004;24:209–223
  93. Bristow RE , del Carmen MG , Pannu HK , et al.   Clinically occult recurrent ovarian cancer (patient selection for secondary cytoreductive surgery using combined PET/CT) . Gynecol Oncol . 2003;90:519–528
  94. Torizuka T , Kanno T , Futatsubashi M , et al.   Imaging of gynecologic tumors (Comparison of (11)C-choline PET with (18)F-FDG PET) . J Nucl Med . 2003;44:1051–1056
  95. Lapela M , Lekinen-Kallio S , Varpula M , et al.   Metabolic imaging of ovarian tumors with carbon-11-methionine (a PET study) . J Nucl Med . 1995;36:2196–2200
  96. Karlan BY , Hoh C , Tse N , et al.   Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube . Gynecol Oncol . 1993;49:383–388
  97. Patel PV , Cohade C , Chin BB . PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma . Gynecol Oncol . 2002;87:323–326
  98. van Leeuwen BL , Pruim J , Gouw AS , et al.   Liver metastasis as a first sign of fallopian tube carcinoma and the role of positron emission tomography in preoperative diagnosis . Scand J Gastroeneterol . 2002;37:1473–1474
  99. Beaulieu S , Boucher L , Lecompte M , et al.   Fluorine-18 fluorodeoxyglucose positron emission tomography correlated with computed tomographic scan and magnetic resonance imaging in a case of hematometrocolpos . Clin Nucl Med . 2000;25:486–487
  100. Sohaib SA , Moskovic EC . Imaging in vulval cancer . Best Prac Res Clin Obstet Gynecol . 2003;17:543–556
  101. Kao CH . Detecting vulvar cancer with inguinal lymph node metastases by dual-phase Tl-201 scan . Clin Nucl Med . 2003;28:80
  102. Cohn DE , Dehdashti F , Gibb RK , et al.   Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer . Gynecol Oncol . 2002;85:179–184
  103. Frank IN , Graham SD , Nabors WL . Urologic and male genital cancers . In:  Holleb AI ,  Fink DJ ,  Murphy GP editor. Clinical Oncology . Atlanta, GA: American Cancer Society; 1991;p. 271–289
  104. Lawton AJ , Mead GM . Staging and prognostic factors in testicular cancer . Semin Surg Oncol . 1999;17:223–229
  105. Hartmann JT , Schmoll HJ , Kuczyk MA , et al.   Postchemotherapy resections of residual masses from metastatic nonseminomatous testicular germ cell tumors . Ann Oncol . 1997;8:531–538
  106. Pandit-Taskar N , Sinha A , Gonen M , et al.   Testicular uptake in 18FDG PET scan . J Nucl Med . 2003;5(suppl):143P
  107. Yun M , Jang S , Kim W , et al.   Pattern of testicular uptake with age and the effect of chemotherapy on testicular uptake determined by FDG PET . J Nucl Med . 2001;5(suppl):287P
  108. Huddart RA . Use of FDG-PET in testicular tumors . Clin Oncol (R Coll Radiol) . 2003;15:123–127
  109. Wolf G , Aigner RM , Schwarz T , et al.   Diagnosis of a contralateral second testicular carcinoma by F18-FDG PET . Onkologie . 2003;26:155–157
  110. Reinhardt MJ , Matthies A , Biersack HJ . PET-imaging in tumors of the reproductive tract . Q J Nucl Med . 2002;46:105–112
  111. Albers P , Bender H , Yilmaz H , et al.   Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors . Urology . 1999;53:808–811
  112. Hain SF , OʼDoherty MJ , Timothy AR , et al.   Fluorodeoxyglucose PET in the initial staging of germ cell tumors . Eur J Nucl Med . 2000;27:590–594
  113. Cremerius U , Wildberger JE , Borchers H , et al.   Dose positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients . Urology . 1999;54:900–904
  114. Cremerius U , Effert PJ , Adam G , et al.   FDG PET for detection and therapy control of metastatic germ cell tumor . J Nucl Med . 1998;39:815–822
  115. Sanchez D , Zudaire JJ , Fernandez JM , et al.   18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumors at relapse . BJU Int . 2002;89:912–916
  116. Lassen U , Daugaard G , Eigtved A , et al.   Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumors . Eur J Nucl Med Mol Imaging . 2003;396–402
  117. Spermon JR , De Geus-Oei LF , Kiemeney LA , et al.   The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumors . BJU Int . 2002;89:549–556
  118. Tsatalpas P , Beuthien-Baumann B , Kropp J , et al.   Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors . Urol Int . 2002;68:157–163
  119. Bokemeyer C , Kollmannsberger C , Oechsle K , et al.   Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET . Br J Cancer . 2002;86:506–511
  120. De Santis M , Bokemeyer C , Becherer A , et al.   Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma . J Clin Oncol . 2001;19:3740–3744
  121. Hain SF , OʼDoherty MJ , Timothy AR , et al.   Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumors at relapse . Br J Cancer . 2000;83:863–869
  122. Ganjoo KN , Chan RJ , Sharma M , et al.   Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma . J Clin Oncol . 1999;17:3457–3460
  123. Muller-Mattheis V , Reinhardt M , Gerharz CD , et al.   Positron emission tomography with [18F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors . Urologe A . 1998;37:609–620
  124. Vesselle HJ , Miraldi FD . FDG PET of the retroperitoneum (normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls) . Radiographics . 1998;18:805–823
  125. Muggia FM , Conti PS . Seminoma and sarcoidosis (a cause for false positive mediastinal uptake in PET?) . Ann Oncol . 1998;9:924
  126. Karapetis CS , Strickland AH , Yip D , et al.   Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumor following chemotherapy (single-center experience with long-term follow up) . Intern Med J . 2003;33:427–435
  127. Nuutinen JM , Leskinen S , Elomaa I , et al.   Detection of residual tumors in postchemotherapy testicular cancer by FDG-PET . Eur J Cancer . 1997;33:1234–1241
  128. Reinhardt MJ , Muller-Mattheis VG , Gerharz CD , et al.   FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy . J Nucl Med . 1997;38:99–101
  129. Wilson CB , Young HE , Ott RJ , et al.   Imaging metastatic testicular germ cell tumors with 18FDG positron emission tomography (prospects for detection and management) . Eur J Nucl Med . 1995;22:508–513
  130. Tatlidil R , Jadvar H , Conti PS . Utility of FDG-PET in the evaluation of residual or recurrent testicular carcinoma (comparison to CT and serum tumor markers) . Radiology . 2000;217:220
  131. Potharaju SP , Smith GT , Hall NC , et al.   Utility of FDG PET in management of testicular cancer and prediction of treatment response . J Nucl Med . 2002;5(suppl):118P
  132. de Geus-Oei LF , Spermon JR , Kiemeney LA , et al.   Chemotherapy response monitoring with 18FDG-PET in patients with high stage testicular germ cell cancer . J Nucl Med . 2003;5(suppl):131P
  133. Becherer A , De Santis M , Bokemeyer C , et al.   FDG-PET as prognostic indicator for seminoma residuals (An update from the SEMPET trial) . J Nucl Med . 2003;5(suppl):174P
  134. Meyer CA , Conces DJ . Imaging of intrathoracic metastases of nonseminomatous germ cell tumors . Chest Surg Clin N Am . 2002;12:717–738
  135. Kole AC , Hoekstra HJ , Sleijfer DT , et al.   L-[1-carbon-11]tyrosine imaging of metastatic testicular nonseminoma germ cell tumors . J Nucl Med . 1998;39:1027–1029
  136. Nguyen BD . PET imaging of Sertoli cell tumor in androgen insensitivity syndrome . Clin Nucl Med . 2003;28:743–745
  137. Ravizzini GC , Wagner M , Borges-Neto S . Positron emission tomography detection of metastatic penile squamous cell carcinoma . J Urol . 2001;165:1633–1634

PII: S0001-2998(04)00041-8

doi: 10.1053/j.semnuclmed.2004.06.003

Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 262-273 , October 2004

Article Tools

* Image Usage & Resolution